Position paper on screening for breast cancer by the European Society of Breast Imaging (EUSOBI) and 30 national breast radiology bodies from Austria, Belgium, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Israel, Lithuania, Moldova, The Netherlands, Norway, Poland, Portugal, Romania, Serbia, Slovakia, Spain, Sweden, Switzerland and Turkey

Francesco Sardanelli, Hildegunn S. Aase, Marina Álvarez, Edward Azavedo, Henk J. Baarslag, Corinne Balleyguier, Pascal A. Baltzer, Vanesa Beslagic, Ulrich Bick, Dragana Bogdanovic-Stojanovic, Ruta Briediene, Boris Brkljacic, Julia Camps Herrero, Catherine Colin, Eleanor Cornford, Jan Danes, Gérard de Geer, Gul Esen, Andrew Evans, Michael H. Fuchsjaeger & 31 others Fiona J. Gilbert, Oswald Graf, Gormlaith Hargaden, Thomas H. Helbich, Sylvia H. Heywang-Köbrunner, Valentin Ivanov, Ásbjörn Jónsson, Christiane K. Kuhl, Eugenia C. Lisencu, Elzbieta Luczynska, Ritse M. Mann, Jose C. Marques, Laura Martincich, Margarete Mortier, Markus Müller-Schimpfle, Katalin Ormandi, Pietro Panizza, Federica Pediconi, Ruud M. Pijnappel, Katja Pinker, Tarja Rissanen, Natalia Rotaru, Gianni Saguatti, Tamar Sella, Jana Slobodníková, Maret Talk, Patrice Taourel, Rubina M. Trimboli, Ilse Vejborg, Athina Vourtsis, Gabor Forrai

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Abstract: EUSOBI and 30 national breast radiology bodies support mammography for population-based screening, demonstrated to reduce breast cancer (BC) mortality and treatment impact. According to the International Agency for Research on Cancer, the reduction in mortality is 40 % for women aged 50–69 years taking up the invitation while the probability of false-positive needle biopsy is <1 % per round and overdiagnosis is only 1–10 % for a 20-year screening. Mortality reduction was also observed for the age groups 40–49 years and 70–74 years, although with “limited evidence”. Thus, we firstly recommend biennial screening mammography for average-risk women aged 50–69 years; extension up to 73 or 75 years, biennially, is a second priority, from 40–45 to 49 years, annually, a third priority. Screening with thermography or other optical tools as alternatives to mammography is discouraged. Preference should be given to population screening programmes on a territorial basis, with double reading. Adoption of digital mammography (not film-screen or phosphor-plate computer radiography) is a priority, which also improves sensitivity in dense breasts. Radiologists qualified as screening readers should be involved in programmes. Digital breast tomosynthesis is also set to become “routine mammography” in the screening setting in the next future. Dedicated pathways for high-risk women offering breast MRI according to national or international guidelines and recommendations are encouraged. Key points: • EUSOBI and 30 national breast radiology bodies support screening mammography. • A first priority is double-reading biennial mammography for women aged 50–69 years. • Extension to 73–75 and from 40–45 to 49 years is also encouraged. • Digital mammography (not film-screen or computer radiography) should be used. • DBT is set to become “routine mammography” in the screening setting in the next future.

Original languageEnglish
Pages (from-to)1-7
Number of pages7
JournalEuropean Radiology
DOIs
Publication statusAccepted/In press - Nov 2 2016

Fingerprint

Moldova
Bosnia and Herzegovina
Estonia
Lithuania
Serbia
Iceland
Bulgaria
Romania
Slovakia
Croatia
Portugal
Hungary
Austria
Czech Republic
Greece
Belgium
Israel
Poland
Mammography
Denmark

Keywords

  • Breast cancer
  • Digital breast tomosynthesis (DBT)
  • Digital mammography
  • Population-based screening
  • Recall rate

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Position paper on screening for breast cancer by the European Society of Breast Imaging (EUSOBI) and 30 national breast radiology bodies from Austria, Belgium, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Israel, Lithuania, Moldova, The Netherlands, Norway, Poland, Portugal, Romania, Serbia, Slovakia, Spain, Sweden, Switzerland and Turkey. / Sardanelli, Francesco; Aase, Hildegunn S.; Álvarez, Marina; Azavedo, Edward; Baarslag, Henk J.; Balleyguier, Corinne; Baltzer, Pascal A.; Beslagic, Vanesa; Bick, Ulrich; Bogdanovic-Stojanovic, Dragana; Briediene, Ruta; Brkljacic, Boris; Camps Herrero, Julia; Colin, Catherine; Cornford, Eleanor; Danes, Jan; de Geer, Gérard; Esen, Gul; Evans, Andrew; Fuchsjaeger, Michael H.; Gilbert, Fiona J.; Graf, Oswald; Hargaden, Gormlaith; Helbich, Thomas H.; Heywang-Köbrunner, Sylvia H.; Ivanov, Valentin; Jónsson, Ásbjörn; Kuhl, Christiane K.; Lisencu, Eugenia C.; Luczynska, Elzbieta; Mann, Ritse M.; Marques, Jose C.; Martincich, Laura; Mortier, Margarete; Müller-Schimpfle, Markus; Ormandi, Katalin; Panizza, Pietro; Pediconi, Federica; Pijnappel, Ruud M.; Pinker, Katja; Rissanen, Tarja; Rotaru, Natalia; Saguatti, Gianni; Sella, Tamar; Slobodníková, Jana; Talk, Maret; Taourel, Patrice; Trimboli, Rubina M.; Vejborg, Ilse; Vourtsis, Athina; Forrai, Gabor.

In: European Radiology, 02.11.2016, p. 1-7.

Research output: Contribution to journalArticle

Sardanelli, F, Aase, HS, Álvarez, M, Azavedo, E, Baarslag, HJ, Balleyguier, C, Baltzer, PA, Beslagic, V, Bick, U, Bogdanovic-Stojanovic, D, Briediene, R, Brkljacic, B, Camps Herrero, J, Colin, C, Cornford, E, Danes, J, de Geer, G, Esen, G, Evans, A, Fuchsjaeger, MH, Gilbert, FJ, Graf, O, Hargaden, G, Helbich, TH, Heywang-Köbrunner, SH, Ivanov, V, Jónsson, Á, Kuhl, CK, Lisencu, EC, Luczynska, E, Mann, RM, Marques, JC, Martincich, L, Mortier, M, Müller-Schimpfle, M, Ormandi, K, Panizza, P, Pediconi, F, Pijnappel, RM, Pinker, K, Rissanen, T, Rotaru, N, Saguatti, G, Sella, T, Slobodníková, J, Talk, M, Taourel, P, Trimboli, RM, Vejborg, I, Vourtsis, A & Forrai, G 2016, 'Position paper on screening for breast cancer by the European Society of Breast Imaging (EUSOBI) and 30 national breast radiology bodies from Austria, Belgium, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Israel, Lithuania, Moldova, The Netherlands, Norway, Poland, Portugal, Romania, Serbia, Slovakia, Spain, Sweden, Switzerland and Turkey', European Radiology, pp. 1-7. https://doi.org/10.1007/s00330-016-4612-z
Sardanelli, Francesco ; Aase, Hildegunn S. ; Álvarez, Marina ; Azavedo, Edward ; Baarslag, Henk J. ; Balleyguier, Corinne ; Baltzer, Pascal A. ; Beslagic, Vanesa ; Bick, Ulrich ; Bogdanovic-Stojanovic, Dragana ; Briediene, Ruta ; Brkljacic, Boris ; Camps Herrero, Julia ; Colin, Catherine ; Cornford, Eleanor ; Danes, Jan ; de Geer, Gérard ; Esen, Gul ; Evans, Andrew ; Fuchsjaeger, Michael H. ; Gilbert, Fiona J. ; Graf, Oswald ; Hargaden, Gormlaith ; Helbich, Thomas H. ; Heywang-Köbrunner, Sylvia H. ; Ivanov, Valentin ; Jónsson, Ásbjörn ; Kuhl, Christiane K. ; Lisencu, Eugenia C. ; Luczynska, Elzbieta ; Mann, Ritse M. ; Marques, Jose C. ; Martincich, Laura ; Mortier, Margarete ; Müller-Schimpfle, Markus ; Ormandi, Katalin ; Panizza, Pietro ; Pediconi, Federica ; Pijnappel, Ruud M. ; Pinker, Katja ; Rissanen, Tarja ; Rotaru, Natalia ; Saguatti, Gianni ; Sella, Tamar ; Slobodníková, Jana ; Talk, Maret ; Taourel, Patrice ; Trimboli, Rubina M. ; Vejborg, Ilse ; Vourtsis, Athina ; Forrai, Gabor. / Position paper on screening for breast cancer by the European Society of Breast Imaging (EUSOBI) and 30 national breast radiology bodies from Austria, Belgium, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Israel, Lithuania, Moldova, The Netherlands, Norway, Poland, Portugal, Romania, Serbia, Slovakia, Spain, Sweden, Switzerland and Turkey. In: European Radiology. 2016 ; pp. 1-7.
@article{d01890a7bd7742d6ade8b694a672baf0,
title = "Position paper on screening for breast cancer by the European Society of Breast Imaging (EUSOBI) and 30 national breast radiology bodies from Austria, Belgium, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Israel, Lithuania, Moldova, The Netherlands, Norway, Poland, Portugal, Romania, Serbia, Slovakia, Spain, Sweden, Switzerland and Turkey",
abstract = "Abstract: EUSOBI and 30 national breast radiology bodies support mammography for population-based screening, demonstrated to reduce breast cancer (BC) mortality and treatment impact. According to the International Agency for Research on Cancer, the reduction in mortality is 40 {\%} for women aged 50–69 years taking up the invitation while the probability of false-positive needle biopsy is <1 {\%} per round and overdiagnosis is only 1–10 {\%} for a 20-year screening. Mortality reduction was also observed for the age groups 40–49 years and 70–74 years, although with “limited evidence”. Thus, we firstly recommend biennial screening mammography for average-risk women aged 50–69 years; extension up to 73 or 75 years, biennially, is a second priority, from 40–45 to 49 years, annually, a third priority. Screening with thermography or other optical tools as alternatives to mammography is discouraged. Preference should be given to population screening programmes on a territorial basis, with double reading. Adoption of digital mammography (not film-screen or phosphor-plate computer radiography) is a priority, which also improves sensitivity in dense breasts. Radiologists qualified as screening readers should be involved in programmes. Digital breast tomosynthesis is also set to become “routine mammography” in the screening setting in the next future. Dedicated pathways for high-risk women offering breast MRI according to national or international guidelines and recommendations are encouraged. Key points: • EUSOBI and 30 national breast radiology bodies support screening mammography. • A first priority is double-reading biennial mammography for women aged 50–69 years. • Extension to 73–75 and from 40–45 to 49 years is also encouraged. • Digital mammography (not film-screen or computer radiography) should be used. • DBT is set to become “routine mammography” in the screening setting in the next future.",
keywords = "Breast cancer, Digital breast tomosynthesis (DBT), Digital mammography, Population-based screening, Recall rate",
author = "Francesco Sardanelli and Aase, {Hildegunn S.} and Marina {\'A}lvarez and Edward Azavedo and Baarslag, {Henk J.} and Corinne Balleyguier and Baltzer, {Pascal A.} and Vanesa Beslagic and Ulrich Bick and Dragana Bogdanovic-Stojanovic and Ruta Briediene and Boris Brkljacic and {Camps Herrero}, Julia and Catherine Colin and Eleanor Cornford and Jan Danes and {de Geer}, G{\'e}rard and Gul Esen and Andrew Evans and Fuchsjaeger, {Michael H.} and Gilbert, {Fiona J.} and Oswald Graf and Gormlaith Hargaden and Helbich, {Thomas H.} and Heywang-K{\"o}brunner, {Sylvia H.} and Valentin Ivanov and {\'A}sbj{\"o}rn J{\'o}nsson and Kuhl, {Christiane K.} and Lisencu, {Eugenia C.} and Elzbieta Luczynska and Mann, {Ritse M.} and Marques, {Jose C.} and Laura Martincich and Margarete Mortier and Markus M{\"u}ller-Schimpfle and Katalin Ormandi and Pietro Panizza and Federica Pediconi and Pijnappel, {Ruud M.} and Katja Pinker and Tarja Rissanen and Natalia Rotaru and Gianni Saguatti and Tamar Sella and Jana Slobodn{\'i}kov{\'a} and Maret Talk and Patrice Taourel and Trimboli, {Rubina M.} and Ilse Vejborg and Athina Vourtsis and Gabor Forrai",
year = "2016",
month = "11",
day = "2",
doi = "10.1007/s00330-016-4612-z",
language = "English",
pages = "1--7",
journal = "European Radiology",
issn = "0938-7994",
publisher = "Springer Verlag",

}

TY - JOUR

T1 - Position paper on screening for breast cancer by the European Society of Breast Imaging (EUSOBI) and 30 national breast radiology bodies from Austria, Belgium, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Israel, Lithuania, Moldova, The Netherlands, Norway, Poland, Portugal, Romania, Serbia, Slovakia, Spain, Sweden, Switzerland and Turkey

AU - Sardanelli, Francesco

AU - Aase, Hildegunn S.

AU - Álvarez, Marina

AU - Azavedo, Edward

AU - Baarslag, Henk J.

AU - Balleyguier, Corinne

AU - Baltzer, Pascal A.

AU - Beslagic, Vanesa

AU - Bick, Ulrich

AU - Bogdanovic-Stojanovic, Dragana

AU - Briediene, Ruta

AU - Brkljacic, Boris

AU - Camps Herrero, Julia

AU - Colin, Catherine

AU - Cornford, Eleanor

AU - Danes, Jan

AU - de Geer, Gérard

AU - Esen, Gul

AU - Evans, Andrew

AU - Fuchsjaeger, Michael H.

AU - Gilbert, Fiona J.

AU - Graf, Oswald

AU - Hargaden, Gormlaith

AU - Helbich, Thomas H.

AU - Heywang-Köbrunner, Sylvia H.

AU - Ivanov, Valentin

AU - Jónsson, Ásbjörn

AU - Kuhl, Christiane K.

AU - Lisencu, Eugenia C.

AU - Luczynska, Elzbieta

AU - Mann, Ritse M.

AU - Marques, Jose C.

AU - Martincich, Laura

AU - Mortier, Margarete

AU - Müller-Schimpfle, Markus

AU - Ormandi, Katalin

AU - Panizza, Pietro

AU - Pediconi, Federica

AU - Pijnappel, Ruud M.

AU - Pinker, Katja

AU - Rissanen, Tarja

AU - Rotaru, Natalia

AU - Saguatti, Gianni

AU - Sella, Tamar

AU - Slobodníková, Jana

AU - Talk, Maret

AU - Taourel, Patrice

AU - Trimboli, Rubina M.

AU - Vejborg, Ilse

AU - Vourtsis, Athina

AU - Forrai, Gabor

PY - 2016/11/2

Y1 - 2016/11/2

N2 - Abstract: EUSOBI and 30 national breast radiology bodies support mammography for population-based screening, demonstrated to reduce breast cancer (BC) mortality and treatment impact. According to the International Agency for Research on Cancer, the reduction in mortality is 40 % for women aged 50–69 years taking up the invitation while the probability of false-positive needle biopsy is <1 % per round and overdiagnosis is only 1–10 % for a 20-year screening. Mortality reduction was also observed for the age groups 40–49 years and 70–74 years, although with “limited evidence”. Thus, we firstly recommend biennial screening mammography for average-risk women aged 50–69 years; extension up to 73 or 75 years, biennially, is a second priority, from 40–45 to 49 years, annually, a third priority. Screening with thermography or other optical tools as alternatives to mammography is discouraged. Preference should be given to population screening programmes on a territorial basis, with double reading. Adoption of digital mammography (not film-screen or phosphor-plate computer radiography) is a priority, which also improves sensitivity in dense breasts. Radiologists qualified as screening readers should be involved in programmes. Digital breast tomosynthesis is also set to become “routine mammography” in the screening setting in the next future. Dedicated pathways for high-risk women offering breast MRI according to national or international guidelines and recommendations are encouraged. Key points: • EUSOBI and 30 national breast radiology bodies support screening mammography. • A first priority is double-reading biennial mammography for women aged 50–69 years. • Extension to 73–75 and from 40–45 to 49 years is also encouraged. • Digital mammography (not film-screen or computer radiography) should be used. • DBT is set to become “routine mammography” in the screening setting in the next future.

AB - Abstract: EUSOBI and 30 national breast radiology bodies support mammography for population-based screening, demonstrated to reduce breast cancer (BC) mortality and treatment impact. According to the International Agency for Research on Cancer, the reduction in mortality is 40 % for women aged 50–69 years taking up the invitation while the probability of false-positive needle biopsy is <1 % per round and overdiagnosis is only 1–10 % for a 20-year screening. Mortality reduction was also observed for the age groups 40–49 years and 70–74 years, although with “limited evidence”. Thus, we firstly recommend biennial screening mammography for average-risk women aged 50–69 years; extension up to 73 or 75 years, biennially, is a second priority, from 40–45 to 49 years, annually, a third priority. Screening with thermography or other optical tools as alternatives to mammography is discouraged. Preference should be given to population screening programmes on a territorial basis, with double reading. Adoption of digital mammography (not film-screen or phosphor-plate computer radiography) is a priority, which also improves sensitivity in dense breasts. Radiologists qualified as screening readers should be involved in programmes. Digital breast tomosynthesis is also set to become “routine mammography” in the screening setting in the next future. Dedicated pathways for high-risk women offering breast MRI according to national or international guidelines and recommendations are encouraged. Key points: • EUSOBI and 30 national breast radiology bodies support screening mammography. • A first priority is double-reading biennial mammography for women aged 50–69 years. • Extension to 73–75 and from 40–45 to 49 years is also encouraged. • Digital mammography (not film-screen or computer radiography) should be used. • DBT is set to become “routine mammography” in the screening setting in the next future.

KW - Breast cancer

KW - Digital breast tomosynthesis (DBT)

KW - Digital mammography

KW - Population-based screening

KW - Recall rate

UR - http://www.scopus.com/inward/record.url?scp=84994337281&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994337281&partnerID=8YFLogxK

U2 - 10.1007/s00330-016-4612-z

DO - 10.1007/s00330-016-4612-z

M3 - Article

SP - 1

EP - 7

JO - European Radiology

JF - European Radiology

SN - 0938-7994

ER -